1053 related articles for article (PubMed ID: 17687326)
1. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
2. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
Bett JS; Goellner GM; Woodman B; Pratt G; Rechsteiner M; Bates GP
Hum Mol Genet; 2006 Jan; 15(1):33-44. PubMed ID: 16311253
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain.
Díaz-Hernández M; Valera AG; Morán MA; Gómez-Ramos P; Alvarez-Castelao B; Castaño JG; Hernández F; Lucas JJ
J Neurochem; 2006 Sep; 98(5):1585-96. PubMed ID: 16787406
[TBL] [Abstract][Full Text] [Related]
4. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
[TBL] [Abstract][Full Text] [Related]
5. Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism.
Wong HK; Bauer PO; Kurosawa M; Goswami A; Washizu C; Machida Y; Tosaki A; Yamada M; Knöpfel T; Nakamura T; Nukina N
Hum Mol Genet; 2008 Oct; 17(20):3223-35. PubMed ID: 18658163
[TBL] [Abstract][Full Text] [Related]
6. The ubiquitin-proteasome system in Huntington's disease.
Valera AG; Díaz-Hernández M; Hernández F; Ortega Z; Lucas JJ
Neuroscientist; 2005 Dec; 11(6):583-94. PubMed ID: 16282599
[TBL] [Abstract][Full Text] [Related]
7. Presynaptic dysfunction in Huntington's disease.
Rozas JL; Gómez-Sánchez L; Tomás-Zapico C; Lucas JJ; Fernández-Chacón R
Biochem Soc Trans; 2010 Apr; 38(2):488-92. PubMed ID: 20298208
[TBL] [Abstract][Full Text] [Related]
8. Generalized brain and skin proteasome inhibition in Huntington's disease.
Seo H; Sonntag KC; Isacson O
Ann Neurol; 2004 Sep; 56(3):319-28. PubMed ID: 15349858
[TBL] [Abstract][Full Text] [Related]
9. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
Bowman AB; Yoo SY; Dantuma NP; Zoghbi HY
Hum Mol Genet; 2005 Mar; 14(5):679-91. PubMed ID: 15661755
[TBL] [Abstract][Full Text] [Related]
10. The DNA repair-ubiquitin-associated HR23 proteins are constituents of neuronal inclusions in specific neurodegenerative disorders without hampering DNA repair.
Bergink S; Severijnen LA; Wijgers N; Sugasawa K; Yousaf H; Kros JM; van Swieten J; Oostra BA; Hoeijmakers JH; Vermeulen W; Willemsen R
Neurobiol Dis; 2006 Sep; 23(3):708-16. PubMed ID: 16860562
[TBL] [Abstract][Full Text] [Related]
11. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
12. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
[TBL] [Abstract][Full Text] [Related]
13. Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin.
Fischer DF; van Dijk R; van Tijn P; Hobo B; Verhage MC; van der Schors RC; Li KW; van Minnen J; Hol EM; van Leeuwen FW
Neurobiol Aging; 2009 Jun; 30(6):847-63. PubMed ID: 18760506
[TBL] [Abstract][Full Text] [Related]
14. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
Crocker SF; Costain WJ; Robertson HA
Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
[TBL] [Abstract][Full Text] [Related]
15. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
16. The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.
Hol EM; van Leeuwen FW; Fischer DF
Trends Mol Med; 2005 Nov; 11(11):488-95. PubMed ID: 16213790
[TBL] [Abstract][Full Text] [Related]
17. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
Seo H; Kim W; Isacson O
Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
[TBL] [Abstract][Full Text] [Related]
18. Recent advances on the pathogenesis of Huntington's disease.
Petersén A; Mani K; Brundin P
Exp Neurol; 1999 May; 157(1):1-18. PubMed ID: 10222105
[TBL] [Abstract][Full Text] [Related]
19. Does impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease?
Matsuda N; Tanaka K
J Alzheimers Dis; 2010; 19(1):1-9. PubMed ID: 20061621
[TBL] [Abstract][Full Text] [Related]
20. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease.
Bett JS; Cook C; Petrucelli L; Bates GP
PLoS One; 2009; 4(4):e5128. PubMed ID: 19352500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
